Please login to the form below
evolucumab
This page shows the latest evolucumab news and features for those working in and with pharma, biotech and healthcare.
Amgen's Repatha unclogs blocked arteries, says study
Looks to boost sales after trial shows clear clinical advantage of PCSK9 inhibitor over statins
Latest news
-
SMC rejects Amgen's Repatha over lack of outcomes data
But gives GlaxoSmithKline’s asthma drug Nucala the green light. The Scottish Medicines Consortium (SMC) has turned down Amgen's cholesterol-lowering treatment Repatha (evolucumab), citing a lack of “robust” data.
-
NICE persuaded to back Praluent as well as Repatha
drug. The scheme includes an undisclosed discount to the NHS and allows NICE to back Praluent and Amgen's rival Repatha (evolucumab), which had already agreed a price cut, in new
SMC rejects Amgen's Repatha over lack of outcomes data
NICE persuaded to back Praluent as well as Repatha
More from news
Approximately 3 fully matching, plus 0 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
-
Digital account director
-
Competitive
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
- Client Services Director +, Remote or London – Leadership Opport...
-
Highly Competitive Salary, Bonus &Benefits
-
Digital strategist
-
Competitive
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
- FREELANCE (Outside IR35) Opportunities for this week below!!!
-
Superb Day Rate
-
Digital project manager
-
Competitive
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
- Israel study suggests Pfizer/BioNTech vaccine is less effective against Delta variant
- Bayer’s BlueRock Therapeutics gains FDA fast track for Parkinson’s disease cell therapy
- FDA advisory committee votes against approval of AZ, FibroGen's roxadustat
- GSK reveals plans for £400m R&D facility expansion in England
- bluebird bio to restart marketing of Zynteglo in EU after previous suspension
- FDA leaders offer perspective on accelerated approval of Biogen’s Aduhelm
- Pfizer and Arvinas announce $1bn deal for investigational oral protein degrader
- Roche engaged in talks with FDA for Alzheimer’s drug candidate
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- The future of work has been just around the corner for some time...
- Investigating the Complexities of the Canadian & Global Health Systems
- Impetus Digital Overview
- FDA advisory committee votes against approval of AZ, FibroGen's roxadustat
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- UK’s CMA fines drugmakers £260m for overcharging NHS for steroid med
- Keytruda scores a win in treating early-stage breast cancer pre- and post-surgery
- Pfizer and Arvinas announce $1bn deal for investigational oral protein degrader
- Pharma’s authentic proof of purpose influences decisions among HCPs and payers
PMHub
Oncosec
OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...
Latest intelligence
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
- The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
- Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
- Virtual Speaker Program: A Customer Story
- Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....
